


# FOCAL CRYOABLATION PROSTATE

A repeatable, effective and minimally  
invasive therapy

*Click to select a topic*

- 1 Overview of Focal Prostate Cryoablation
- 2 Clinical Results
- 3 Cryoablation Needles: Isotherm Data 37° Gel



Images courtesy of Taimur Shah,  
Imperial College London,  
University College London, UK



# 1 Overview of Focal Prostate Cryoablation

## INNOVATION IN ABLATION

Building on Boston Scientific's commitment in Interventional Oncology, we have expanded our portfolio of minimally invasive therapies with the leading technology in cryoablation.

- Flexibility of needle options to tailor your treatment
- Precise control allows you to sculpt the optimal ablation zone
- Progressive cryoablation software platform simplifies procedure
- Advanced technology drives innovative capabilities

Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function.

Tay KJ et al. 2017<sup>1</sup>

## A REPEATABLE, EFFECTIVE AND MINIMALLY INVASIVE THERAPY


### OVERVIEW

- High disease control rates<sup>1-4</sup>
- Low incontinence rates<sup>2-13</sup>
- Preservation of erectile function<sup>1-5, 10-16</sup>
- Repeatable<sup>2,17,18</sup>
- Fast recovery times<sup>5</sup>
- Low morbidity<sup>2,6,7</sup>

Focal cryoablation can provide *biochemical and local control* of prostate cancer while preserving *potency and continence*.

Bahn DK et al. 2006<sup>4</sup>

ANTERIOR BILATERAL FOCAL CRYOTHERAPY  
Controlled growth of iceballs minimises risk of damage to neurovascular bundles, while warming catheter offers sphincteric and urethral protection



Images courtesy of Taimur Shah, Imperial College London, University College London, UK



## 1 Overview of Focal Prostate Cryoablation (cont.)

### FOCAL PROSTATE CRYOTHERAPY:

#### THE TREATMENT OF CHOICE FOR ANTERIOR LESIONS

- Excellent preservation of functional outcomes:<sup>2,19</sup>
  - 100% continence preservation
  - >80% preservation of erectile function
  - 0% rectal injury
- Established oncologic efficacy

#### THE LIMITATIONS OF HIFU FOR ANTERIOR PROSTATIC LESIONS<sup>20</sup>

- Ultrasound waves dissipate over longer focal distances
- Intervening prostatic tissue undergoes edema, pushing target tissue further away
- No evidence that treatment of apical tumours is incontinence free

*The ease of accessibility via transperineal needles and established oncologic efficacy make **cryotherapy more desirable** [than other focal therapies] for cancers in **anterior locations**.*

**Sivaraman A et al. 2016<sup>20</sup>**


*If the oncological outcomes are maintained, then it can be argued that the **first-line** treatment option for **anterior prostate cancer** should be **focal cryotherapy**.*

**Shah T. 2017<sup>19</sup>**



2 Clinical Results

BIOCHEMICAL PROGRESSION-FREE SURVIVAL AND PRESERVATION OF CONTINENCE AND ERECTILE FUNCTION†



URINARY RETENTION AND FISTULA† (if reported)

†Results shown are those reported at longest follow-up point recorded in publication

...focal cryotherapy may be a suitable *alternative treatment option* to radical whole-gland surgery or radiotherapy in men wishing to *preserve sexual function*.

Shah T. 2017<sup>3</sup>


A major strength of our data comes from the fact that the *majority of our cohort had intermediate- and high-risk prostate cancer* in contrast to the early cryotherapy cohorts with predominantly low-risk disease.

Shah T. 2019<sup>2</sup>




### 3 Recommended Cryoablation Needles: Isotherm Data 37° Gel

**ICEROD™ 1.5  
CRYOABLATION NEEDLE**  
Optimal spacing: 1.0–1.5 cm



**ICESPHERE™ 1.5  
CRYOABLATION NEEDLE**  
Optimal spacing: 1.0–1.5 cm



*The advantage of cryotherapy is easy accessibility via transperineal needles to all parts of the prostate including the anterior zone.*

**Sivaraman A et al. 2016<sup>20</sup>**

*Focal therapy has recently emerged as a promising management strategy that would ideally selectively target the cancer area and spare the rest of the gland, thereby leading to fewer adverse effects compared with radical therapies.*

**Barret et al. 2013<sup>18</sup>**



## FOR MORE INFORMATION ON CRYOABLATION VISIT US AT [IOABLATION.COM](http://IOABLATION.COM)

1. Tay KJ, Schulman A, Sze C *et al.* *Expert Rev Anticancer Ther* 2017; 17(8): 737-743
2. Shah T *et al.* *Eur Urol*. 2019; 76(1): 98-105
3. Shah T *et al.* Primary focal cryotherapy: A prospective multicenter UK registry study of 135 patients. BAUS ePoster online library. Jun 28, 2017; 177476
4. Bahn DK, Silverman P, Lee F Sr *et al.* *J Endourol* 2006; 20(9): 688-692
5. Bahn D, de Castro Abreu AL, Gill IS *et al.* *Eur Urol* 2012; 62(1): 55-63
6. Katz AE, Rewcastle JC. *Curr Oncol Rep* 2003; 5(3): 231-8
7. Ward JF, Jones JS. *BJU Int* 2012; 109(11): 1648-54
8. Lambert EH, Bolt K, Masson P *et al.* *Urology* 2007; 69(6): 1117-1120
9. Ellis DS, Manny TB Jr, Rewcastle JC. *Urology* 2007; 70(6 Suppl): 9-15
10. Onik G, Vaughan D, Lotenfoe R *et al.* *Urol Oncol* 2008; 26(5): 500-5
11. Truesdale MD, Cheetham PJ, Hruby GW *et al.* *Cancer J* 2010; 16(5): 544-9
12. Hale Z, Miyake M, Palacios DA *et al.* *BMC Urol* 2013 13; 2
13. Barqawi AB, Stoemenova D, Krughoff K *et al.* *J Urol*. 2014; 192(3): 749-53
14. Durand M, Barrett E, Galiano M *et al.* *BJU Int* 2014; 113(1): 56-64
15. Barqawi AB, Huebner E, Krughoff K *et al.* *Urology* 2017; <https://doi.org/10.1016/j.urology.2017.10.029> (epub ahead of print)
16. Tay KJ, Polascik TJ, Elshafei A *et al.* *J Endourol* 2017; 31(6): 564-571
17. Mustafa M, Delacroix S, Ward JF *et al.* *World J Surg Oncol* 2015; 13: 340
18. Barret E, Ahallal Y, Sanchez-Salas R *et al.* *Eur Urol* 2013; 63: 618-22
19. Shah T. "No restriction, no Boundaries. Why Cryotherapy is the Treatment of Choice for Anterior Lesions". Presented at International Focal Therapy in Imaging in Prostate and Kidney Cancer, Noordwijk, The Netherlands, February 2018
20. Sivaraman A, Baret E. *Eur Urol*. 2016; 69: 973-75
21. Lian H, Yang R, Lin T *et al.* *Int Urol Nephrol* 2016; 48(9):1461-6.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Material not intended for use in France.

PI-908204-AB Printed in Germany by medicalvision.

**Boston  
Scientific**  
Advancing science for life™

[www.bostonscientific.eu](http://www.bostonscientific.eu)

© 2020 Boston Scientific Corporation  
or its affiliates. All rights reserved.

